Literature DB >> 25838066

Incidence, Progression, and Associated Risk Factors of Medium Drusen in Age-Related Macular Degeneration: Findings From the 15-Year Follow-up of an Australian Cohort.

Nichole D L Joachim1, Paul Mitchell1, Annette Kifley1, Jie Jin Wang1.   

Abstract

IMPORTANCE: The natural course and prognosis of medium drusen and risk factors associated with the incidence and progression of this lesion type in age-related macular degeneration (AMD) are not well understood.
OBJECTIVE: To assess the 15-year incidence and progression of medium drusen and associated risk factors. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort in the Blue Mountains region, west of Sydney, Australia. Included in the study were 3654 participants 49 years or older who attended baseline examinations of the Blue Mountains Eye Study (1992-1994), and 75.8%, 76.7%, and 56.1% of survivors who attended the 5-year, 10-year, and 15-year follow-up examinations, respectively. MAIN OUTCOMES AND MEASURES: Color retinal fundus photographs were obtained at each examination. The incidence and progression of medium drusen (maximum diameter, 63 to <125 µm) were assessed using Kaplan-Meier product-limit survival methods, controlling for competing risk of death. Factors associated with a 15-year incidence of medium drusen were assessed using discrete logistic regression models after adjusting for age, sex, smoking status, serum lipid levels, systemic and dietary factors, and CFH rs1061170 and ARMS2 rs10490924 polymorphisms. Associations between lesion characteristics and the progression to late AMD were assessed using generalized estimating equation models and eye-specific data.
RESULTS: Among 1317 participants at risk, the 15-year cumulative incidence of medium drusen was 13.9% (n = 281). Increasing age (per decade older) (odds ratio [OR], 1.4; 95% CI, 1.2-1.8) and the presence of at least 3 risk alleles of the CFH rs1061170 or ARMS2 rs10490924 genes (OR, 2.1; 95% CI, 1.1-4.1) were associated with a higher incidence. There was no association between past smoking (OR, 0.8; 95% CI, 0.6-1.1) or current smoking (OR, 0.6; 95% CI, 0.4-1.1) and the development of medium drusen. The progression rate to late AMD in eyes with both medium drusen and retinal pigmentary abnormalities was 4-fold higher than that in eyes with medium drusen alone. Larger total area and central location of medium drusen were associated with a greater likelihood of the progression to worse stages of AMD. CONCLUSIONS AND RELEVANCE: Older age and the presence of CFH and ARMS2 risk alleles are 2 main risk factors associated with the development of medium drusen. The copresence of medium drusen plus retinal pigment epithelium abnormalities signals a greater risk of the progression to late AMD than the presence of medium drusen alone.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25838066     DOI: 10.1001/jamaophthalmol.2015.0498

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  10 in total

1.  Histologic and Optical Coherence Tomographic Correlates in Drusenoid Pigment Epithelium Detachment in Age-Related Macular Degeneration.

Authors:  Chandrakumar Balaratnasingam; Jeffrey D Messinger; Kenneth R Sloan; Lawrence A Yannuzzi; K Bailey Freund; Christine A Curcio
Journal:  Ophthalmology       Date:  2017-01-30       Impact factor: 12.079

2.  Sex and Age-Related Differences in Complement Factors Among Patients With Intermediate Age-Related Macular Degeneration.

Authors:  A Itzam Marin; Felix Poppelaars; Brandie D Wagner; Alan G Palestine; Jennifer L Patnaik; V Michael Holers; Ashley A Frazer-Abel; Marc T Mathias; Niranjan Manoharan; Cheryl N Fonteh; Naresh Mandava; Anne M Lynch
Journal:  Transl Vis Sci Technol       Date:  2022-05-02       Impact factor: 3.048

Review 3.  Optical Coherence Tomography Angiography of Dry Age-Related Macular Degeneration.

Authors:  Nadia K Waheed; Eric M Moult; James G Fujimoto; Philip J Rosenfeld
Journal:  Dev Ophthalmol       Date:  2016-03-15

4.  Activated Retinal Pigment Epithelium, an Optical Coherence Tomography Biomarker for Progression in Age-Related Macular Degeneration.

Authors:  Christine A Curcio; Emma C Zanzottera; Thomas Ach; Chandrakumar Balaratnasingam; K Bailey Freund
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

5.  Genetic Susceptibility, Diet Quality, and Two-Step Progression in Drusen Size.

Authors:  Bénédicte M J Merle; Bernard Rosner; Johanna M Seddon
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-05-11       Impact factor: 4.799

Review 6.  Risk factors for progression of age-related macular degeneration.

Authors:  Thomas J Heesterbeek; Laura Lorés-Motta; Carel B Hoyng; Yara T E Lechanteur; Anneke I den Hollander
Journal:  Ophthalmic Physiol Opt       Date:  2020-02-25       Impact factor: 3.117

7.  Topographic Distribution and Progression of Soft Drusen Volume in Age-Related Macular Degeneration Implicate Neurobiology of Fovea.

Authors:  Andreas Pollreisz; Gregor S Reiter; Hrvoje Bogunovic; Lukas Baumann; Astrid Jakob; Ferdinand G Schlanitz; Stefan Sacu; Cynthia Owsley; Kenneth R Sloan; Christine A Curcio; Ursula Schmidt-Erfurth
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-02-01       Impact factor: 4.799

Review 8.  Role of microperimetry in evaluating disease progression in age-related macular degeneration: a scoping review.

Authors:  Gopinath Madheswaran; Pinaz Nasim; Shonraj Ballae Ganeshrao; Rajiv Raman; Ramesh S Ve
Journal:  Int Ophthalmol       Date:  2022-01-07       Impact factor: 2.029

Review 9.  Artificial Intelligence Analysis of Biofluid Markers in Age-Related Macular Degeneration: A Systematic Review.

Authors:  Aidan Pucchio; Saffire H Krance; Daiana R Pur; Rafael N Miranda; Tina Felfeli
Journal:  Clin Ophthalmol       Date:  2022-08-07

Review 10.  Soft Drusen in Age-Related Macular Degeneration: Biology and Targeting Via the Oil Spill Strategies.

Authors:  Christine A Curcio
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-20       Impact factor: 4.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.